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Immunologic ignorance of vascular endothelial cells expressing
minor histocompatibility antigen
Abstract
Endothelial cells (ECs) presenting minor histocompatibility antigen (mhAg) are major target cells for
alloreactive effector CD8(+) T cells during chronic transplant rejection and graft-versus-host disease
(GVHD). The contribution of ECs to T-cell activation, however, is still a controversial issue. In this
study, we have assessed the antigen-presenting capacity of ECs in vivo using a transgenic mouse model
with beta-galactosidase (beta-gal) expression confined to the vascular endothelium (Tie2-LacZ mice). In
a GVHD-like setting with adoptive transfer of beta-gal-specific T-cell receptor-transgenic T cells,
beta-gal expression by ECs was not sufficient to either activate or tolerize CD8(+) T cells. Likewise,
transplantation of fully vascularized heart or liver grafts from Tie2-LacZ mice into nontransgenic
recipients did not suffice to activate beta-gal-specific CD8(+) T cells, indicating that CD8(+) T-cell
responses against mhAg cannot be initiated by ECs. Moreover, we could show that spontaneous
activation of beta-gal-specific CD8(+) T cells in Tie2-LacZ mice was exclusively dependent on
CD11c(+) dendritic cells (DCs), demonstrating that mhAgs presented by ECs remain immunologically
ignored unless presentation by DCs is granted.
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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Immunologic ignorance of vascular endothelial cells expressing minor
histocompatibility antigen
*Beatrice Bolinger,1 *Philippe Krebs,1 Yinghua Tian,2 Daniel Engeler,1 Elke Scandella,1 Simone Miller,1 Douglas C. Palmer,3
Nicholas P. Restifo,3 Pierre-Alain Clavien,2 and Burkhard Ludewig1
1Research Department, Kantonal Hospital, St Gallen, Switzerland; 2Departement of Visceral Surgery, University Hospital Zurich, Zurich, Switzerland; and
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Endothelial cells (ECs) presenting minor
histocompatibility antigen (mhAg) are ma-
jor target cells for alloreactive effector
CD8 T cells during chronic transplant
rejection and graft-versus-host disease
(GVHD). The contribution of ECs to T-cell
activation, however, is still a controver-
sial issue. In this study, we have as-
sessed the antigen-presenting capacity
of ECs in vivo using a transgenic mouse
model with beta-galactosidase (-gal) ex-
pression confined to the vascular endo-
thelium (Tie2-LacZ mice). In a GVHD-like
setting with adoptive transfer of -gal–
specific T-cell receptor–transgenic T cells,
-gal expression by ECs was not suffi-
cient to either activate or tolerize CD8
T cells. Likewise, transplantation of fully
vascularized heart or liver grafts from
Tie2-LacZ mice into nontransgenic recipi-
ents did not suffice to activate -gal–
specific CD8 T cells, indicating that CD8
T-cell responses against mhAg cannot be
initiated by ECs. Moreover, we could show
that spontaneous activation of -gal–
specific CD8 T cells in Tie2-LacZ mice
was exclusively dependent on CD11c
dendritic cells (DCs), demonstrating that
mhAgs presented by ECs remain immuno-
logically ignored unless presentation by
DCs is granted. (Blood. 2008;111:
4588-4595)
Introduction
Endothelial cells (ECs) act as the major interface between blood
and tissues. Forming the inner lining of blood vessels, they are
uniquely positioned between circulating lymphocytes and the
periphery and thereby regulate the trafficking of T lymphocytes
from the bloodstream to sites of infection and inflammation.
Following transplantation of vascularized organs, ECs are the
first graft cells encountered by activated host lymphocytes and
are therefore primary targets of alloreactive cytotoxic T lympho-
cytes (CTLs).1,2 Since donor ECs persist in vascularized organ
transplants, they may contribute to chronic immune stimulation
and thereby fuel the process of chronic rejection. Such late graft
failure is a major problem in transplantation medicine that
frequently necessitates retransplantation.3 Furthermore, ECs are
important target cells for activated alloreactive CTLs during
graft-versus-host disease (GVHD),4 which is characterized by
large numbers of circulating minor histocompatibility antigen
(mhAg)–specific CTLs.5
ECs can act as antigen-presenting cells (APCs) to CD8 T cells
both via the direct pathway (ie, recognition of allo–major histocom-
patibility complex [MHC]/peptide complexes) or via the indirect
pathway involving cross-presentation of exogenous antigens.6-8 In
vitro studies have demonstrated that both human9 and murine10
ECs can activate resting allogeneic CD8 T cells, suggesting that
ECs critically contribute to the initial stimulation of alloreactive
T lymphocytes.1 Moreover, ECs exhibit important functions of
professional APCs, including expression of MHC class II and
costimulatory molecules11 and cross-presentation of minor histo-
compatibility antigens.6,8 The notion that ECs may under particular
circumstances act as professional APCs has been supported by the
finding that nonhematopoietic cells within vascularized grafts—
presumably ECs—are able to initiate CTL responses that mediate
allograft rejection.12
There are, however, a number of reports challenging the view
that ECs may act as immune activators. Murine lung ECs, for
example, have been shown to negatively regulate CD8 T-cell
function.13 Furthermore, liver sinusoidal ECs can induce CD8
T-cell tolerance to soluble8,14 or tumor-derived antigens.15 A third
possible form of EC-CTL interaction is that of immunologic
ignorance. Indeed, aly/aly mice lacking secondary lymphoid or-
gans fail to reject vascularized organ transplants, even in an
allogeneic setting,16 suggesting that the environment of organized
lymphoid tissues is critical for primary activation of T-cell re-
sponses. To a large extent, these contradictory findings can be
explained by the use of in vitro coculture systems or the lack of an
appropriate in vivo model with truly EC-restricted antigen presen-
tation. An experimental in vivo system with expression of well-
defined antigens exclusively in vascular ECs may therefore be
helpful to solve the question whether antigen presentation by
vascular ECs can lead to activation or tolerization of antigen-
specific CD8 T cells.
The use of antigen-transgenic mice combined with the power of
T-cell receptor (TCR)–transgenic animals has provided important
insight into the basic principles of autoimmunity17,18 and tumor
immunity.19,20 Recently, similar systems have been exploited to
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analyze T-cell responses in different allograft transplantation6,21-23
and GVHD models.24 However, despite significant advances in our
understanding of the antigen-presenting function of nonhematopoi-
etic cells during allograft reactions21 or the importance of T-cell
frequencies for solid organ graft rejection,23,25 the precise role of
mhAg presentation by ECs has remained elusive. We have used
here Tie2-LacZ mice to model mhAg presentation by ECs. In these
mice, the tie2 promotor drives the expression of the beta-
galactosidase (-gal) antigen in ECs in all tissues.26 In vivo
analysis of antigen-specific interaction between ECs and CD8
T cells has been facilitated by using high-affinity -gal–specific
TCR-transgenic CD8 T cells (Bg1 cells). Adoptive transfer of Bg1
CD8 T cells into Tie2-LacZ mice revealed that mhAg presentation
by ECs did not suffice to activate or to tolerize CD8 T cells.
Furthermore, -gal expression by ECs in heterotopically trans-
planted Tie2-LacZ hearts or orthotopically transplanted Tie2-LacZ
livers did not result in CD8 T-cell activation in naive recipients.
Finally, generation of bone marrow (BM) chimeric mice that
facilitated selective ablation of CD11c dendritic cells (DCs)
revealed that EC-associated mhAg has to be cross-presented by
DCs in order to elicit CD8 T-cell activation.
Methods
Mice
Male and female C57BL/6 mice were obtained from Charles River
(Sulzfeld, Germany). Tie2-LacZ mice26 had been backcrossed with C57BL/6
mice at least 14 times. B6.C-H2bm1 mice were provided by Christian Kurts
(University of Bonn, Germany). Bg1 mice were produced with TCR
cassette vectors generously provided by Dr Diane Mathis (Brigham and
Women’s Hospital, Boston, MA). RNA was isolated from a -gal96-103–
specific CD8 T-cell clone, generated by limiting dilution, using silica
matrix columns (Qiagen, Valencia, CA). Known TCR  and  constant
region sequences were used to perform 5 rapid amplification of cDNA ends
(Invitrogen, Carlsbad, CA), and TCR sequences were then cloned into
pCR4TOPO TA cloning sequencing vectors (Invitrogen). The TCR  and 
transcripts were sequenced using an ABI Prism (Perkin-Elmer, Wellesley,
MA), and these sequences were compared with available sequences to
develop genomic cloning polymerase chain reaction (PCR) primers. These
cloning primers provide amplification of the variable domains consisting of
10 to 20 bp upstream of the start codon through 200 to 300 bp of intronic
sequence downstream of the junctional regions, thereby preserving splice
donor/acceptor sites. The  and  genomic variable domains were
PCR-amplified (Perkin-Elmer) and TA-cloned into a sequencing vector
(Invitrogen). The genomic variable domains were sequenced (V1/
JTA13/C and V7S1/J2S4/C2) and subcloned into the TCR cassette
vectors. The  and  cassette vectors were coinjected into fertilized
C57BL/6 embryos (SAIC, Frederick, MD), and founders were obtained.
The resulting mice, named Bg1, were maintained as heterozygotes, as a
high rate of lymphoma in homozygotes reduced their life span. Heterozy-
gotes were bred to B6.SJL mice and transgene expression was monitored by
staining of blood cells with anti-V7 by flow cytometry. Bg1 mice were
further crossed with C57BL/6 mice expressing the congenic marker Thy1.1.
Mice expressing the human high-affinity diphteria toxin receptor (DTR)
under the control of the CD11c promoter27 were provided by Steffen Jung
(The Weizmann Institute of Science, Rehovot, Israel). The presence of the
-gal and DTR transgenes was determined by PCR from genomic DNA;
the presence of the H2-Kbm1 molecule was determined by flow cytometry of
blood lymphocytes using the 5F1 antibody.28 All animals were kept under
conventional conditions in individually ventilated cages and fed with
normal chow diet. Experiments were carried out with age-matched
(6-8 weeks) and sex-matched animals. Experiments were performed in
accordance with Swiss Kantonal and federal legislations and were approved
by the Veterinary Officer of the Kanton of St Gallen.
Viruses and peptides
Recombinant murine cytomegalovirus (MCMV) expressing the -gal
protein under the transcriptional control of the human CMV ie1/ie2
promoter-enhancer (MCMV-LacZ RM42729) was kindly provided by Prof
E. S. Mocarski (Stanford University, Stanford, CA). MCMV-LacZ was
propagated and titrated on NIH 3T3 cells (European Collection of Cell
Cultures, Salisbury, United Kingdom) and injected intravenously at a dose
of 2  106 pfu. -gal96-103 (DAPIYTNV),30 -gal497-504 (ICPMYARV),31
and MCMV M45985-993 (HGIRNASFI)32 peptides were purchased from
Neosystem (Strasbourg, France).
Generation of BM chimeric mice
Recipient mice were lethally irradiated with 9 Gy (900 rad) from a linear
accelerator (Clinic of Radio-Oncology, Kantonal Hospital, St Gallen) and
intravenously injected 1 day later with 2  107 of the indicated donor
BM cells. Chimeric mice were maintained on antibiotic water containing
sulfadoxin and trimethoprim (Veterinaria, Zurich, Switzerland) for the
following 3 weeks. Recipient mice carrying the Kbm1 mutation received
CD4 and CD8 T cell–depleted BM and were further depleted of NK 1.1
cells by intraperitoneal injection of 20 L anti-asialo GM1 antibody (Wako
Pure Chemical Industries, Tokyo, Japan) on the day before and in weekly
intervals for 6 weeks following irradiation. Mice were used for experiments
8 to 10 weeks after BM reconstitution.
Antibodies and flow cytometry
Anti-CD8–FITC, anti-CD4–PerCP, anti-V7–FITC, anti-CD90.1–PE, anti-
CD44–PE, and anti-IFN–PE were obtained from BD PharMingen (Basel,
Switzerland). Anti-CD8–allophycocyanin was obtained from Biolegend
(LuBioScience, Lucerne, Switzerland). Anti-CD62L–PE was obtained from
ImmunoTools (Friesoythe, Germany). For flow cytometry, single-cell
suspensions were generated from the indicated organs and 106 cells were
incubated with the indicated mAb at 4°C for 20 minutes. For peripheral
blood lymphocyte (PBL) samples, erythrocytes were lysed with fluorescence-
activated cell sorter (FACS) Lysing Solution (BD PharMingen). Cells were
analyzed with a FACScalibur flow cytometer using the CellQuest software
(BD Biosciences). The cells were analyzed by flow cytometry, gating on
viable leukocytes using 7-aminoactinomycin D (Sigma, Buchs, Switzerland).
Construction of tetrameric MHC class I peptide complexes and
flow cytometry
MHC class I monomers complexed with -gal (H-2Kb) or M45 peptides
(H-2Db) were produced as previously described33 and tetramerized by
addition of streptavidin-PE (Molecular Probes, Eugene, OR). At the
indicated time points following infection, organs were removed and
single-cell suspensions were prepared. Aliquots of 5  106 cells or 300 L
of blood were stained using 50 L of a solution containing tetrameric class I
peptide complexes at 37°C for 10 minutes, followed by staining with
anti-CD8–FITC (BD PharMingen) at 4°C for 20 minutes. Absolute cell
counts were determined by counting leukocytes in an improved Neubauer
chamber (Sigma).
Chromium release assay
EL-4 cells pulsed with peptide or without peptide (negative control) were
used as target cells in a standard 51Cr release assay. Cells were labeled with
7.4 MBq (200 Ci) 51Cr (EGT Chemie, Ta¨gerig, Switzerland) for 1 hour at
37°C. A total of 104 target cells/well were incubated for 5 hours in 96-well
round bottom plates with 3-fold serial dilutions of effector cells. Spleno-
cytes from MCMV-LacZ–infected mice that were restimulated with the
indicated peptides for 5 days were tested for their cytolytic activity.
Spontaneous chromium release was always below 15%.
CFSE labeling of TCR-transgenic T cells and adoptive transfer
Single-cell suspensions from the spleens of Bg1 mice were subjected to
hypotonic red blood cell lysis and stained with CFSE (Molecular Probes,
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Leiden, The Netherlands). A maximum concentration of 2.5  107 cells/mL
were incubated in 5 M CFSE in phosphate-buffered saline (PBS) for
10 minutes at 37°C. Cells were washed twice with ice-cold balanced salt
solution (BSS) and resuspended in BSS at a concentration of 1.5  107
splenocytes/mL. Recipient B6, Tie2-LacZ, and the different subsets of
chimeric mice were injected intravenously with 1.5  107 Bg1-Thy1.1
splenocytes in 500 L BSS.
Immunohistology
Freshly removed organs were immersed in Hanks BSS (HBSS) and
snap-frozen in liquid nitrogen. Frozen tissue sections were cut in a cryostat
and fixed in acetone for 10 minutes. Sections were incubated with
antibodies against -gal (MP Biomedicals, Irvine, CA) and CD8 (clone
YTS169.4.2), followed by goat anti-rat Ig (Caltag Laboratories, Burlin-
game, CA) and alkaline phosphatase–labeled donkey anti-goat Ig (Jackson
ImmunoResearch Laboratories, West Grove, PA). Alkaline phophatase was
visualized by using AS-BI phosphate/new fuchsin; sections were counter-
stained with hemalum, and images were acquired using a Leica DM R
microscope equipped with a Leica DC300 FX camera (Leica, Heerbrugg,
Switzerland). Digital images were processed using Adobe Photoshop
(Adobe, San Jose, CA).
Surgical procedure for liver transplantation
Donor procedure, back-table preparation, and recipient procedure were per-
formed as described previously with minor modifications.34 Briefly, all vessels
and ligaments of the liver were dissected in the donor after midline laparotomy. In
situ perfusion of the liver was performed using cold (4°C) Ringer solution.
Subsequently, the liver was separated from its retroperitoneal attachments and
removed. The graft was stored in cold (4°C) Ringer solution for 60 minutes until
implantation into the recipient. Following hepatectomy of the native liver in the
recipient, the donor liver was implanted in an orthotopic position. The anhepatic
time in the recipient was consistently kept below 20 minutes. The portal vein was
reconstructed and the liver was reperfused after completing the anastomosis
between the suprahepatic inferior vena cava of the recipient and donor. Arterial
recirculation was established by an end-to-side anastomosis between the recipient
aorta and an aortic segment attached to the hepatic artery of the graft. A single
subcutaneous injection of 5 mg cefazolin provided antibiotic prophylaxis.
Heterotopic heart transplantation
Heterotopic vascularized cardiac transplantation was performed according
to the method described by Corry et al.35 Donor hearts were explanted from
either male Tie2-LacZ or male C57BL/6 mice. The donor heart was
removed from the chest after intracaval injection of 1 mL heparin
(100 U/mL), rinsed with NaCl 0.9%, and placed on ice. After isolation of
the recipient’s abdominal aorta and inferior vena cava, the donor ascending
aorta and pulmonary artery were joined end-to-side to the recipient’s aorta
and vena cava, respectively, using 10-0 nylon running suture. The abdomen
was closed with individual running sutures to musculofascial layer and
skins. The recipient mouse was then warmed for a few hours during
recovery from anesthesia and had free access to water and food. The
function of the transplanted heart was assessed daily by abdominal
palpation.
Statistical data analysis
To evaluate statistically significant differences, the unpaired 2-tailed Student test
was used. P values smaller than .05 were considered statistically significant.
Statistical data analysis was performed using GraphPad Prism version 4.03 for
Windows (GraphPad Software, San Diego CA).
Results
CD8 T-cell tolerance in Tie2-LacZ mice
Currently, a number of transgenic mouse lines are available that
exhibit EC-restricted transgene expression: von Willebrand factor–
LacZ36 and thrombomodulin-LacZ37 mice, which both show patchy
transgene distribution in some arteries; and tie2-H-2Kb mice,14
which express the H2-Kb molecule as a transgene. In this study,
Tie2-LacZ mice26 backcrossed to the C57BL/6 background have
been used because of the uniform -gal Ag expression in ECs of all
organs. It is noteworthy that the intensity of -gal expression in
Tie2-LacZ mice is most pronounced in small and large arteries, but
clearly detectable in venous and capillary ECs (Figure 1A; Figure
S1, available on the Blood website; see the Supplemental Materials
link at the top of the online article). Furthermore, expression levels
of -gal mRNA in various organs were comparable (Figure S2),
indicating that these mice are well suited to study EC–CD8 T-cell
Figure 1. CD8 T-cell reactivity in Tie2-LacZ mice. (A) Heart and thymus sections
of naive Tie2-LacZ mice were stained for -gal and CD8. Images were acquired with
a 25/0.65 objective (magnification: 162). (B,C) C57BL/6 (B6) and Tie2-LacZ (T2)
mice were infected intravenously with 106 pfu MCMV-LacZ. (B) Tetramer analysis for
the indicated -gal– and MCMV-derived M45 epitopes was performed on day 6 after
infection. Mean percentage of tetramer-positive cells within the CD8 compartment
are indicated ( SEM; n 	 3-4). (C) Lysis of peptide-pulsed EL-4 cells by MCMV-LacZ-
induced CTLs. On day 6 after infection, splenocytes from the indicated mouse strains
were restimulated in vitro for 5 days with -gal497-504, -gal96-103, or M45985-993 peptide
and tested in a standard chromium release assay.
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interaction in vivo. Indeed, in a previous study, Rothermel et al38
used Tie2-LacZ mice on the FVB genetic background to assess
CD4 and CD8 T-cell responsiveness under conditions of persist-
ing Ag expression in ECs. Whereas this previous investigation
suggested that Tie2-LacZ mice can mount CD8 T-cell responses
against the EC-restricted -gal Ag,38 the results obtained in the
present study indicate that CD8 T cells in Tie2-LacZ mice are
tolerant to the -gal antigen. This is shown by the fact that
Tie2-LacZ mice failed to mount -gal–specific CTL responses
following infection with -gal–recombinant MCMV (MCMV-
LacZ), whereas CD8 T-cell responses against the viral M45
epitope were not influenced by the EC-specific transgene expres-
sion (Figure 1B,C).
We next addressed whether the apparent-gal–specific CD8T-cell
tolerance in Tie2-LacZ mice is mediated by thymic negative selection or
by peripheral tolerizing mechanisms. To this end, Tie2-LacZ mice were
crossed with TCR-transgenic Bg1 mice, which possess CD8 T cells
that recognize the H2-Kb–restricted -gal96-103 epitope.30 A total of 60%
to 70% of the Bg1 CD8 T cells bind H2-Kb/-gal96-103 tetramers
(Figure 2), and Bg1 CD8 T cells possess a high functional avidity for
the -gal96-103 epitope as shown by target cell recognition and prolifera-
tion assays (Figure S4). In the thymus of Tie2-LacZBg1 mice, the
numbers of transgenic V7 chain–positive and tetramer-binding CD8
cells were reduced to 40% (Figure 2), suggesting that central tolerance
led to partial deletion of -gal–specific T cells. Interestingly, in
peripheral lymphoid organs such as the spleen, the numbers of V7
and -gal96-103 tetramer-binding CD8 T cells was further reduced from
60% to 70% in Bg1 to less than 10% in Tie2-LacZBg1 mice. Thus, at
a first glance, it appears that EC-specific Ag expression in Tie2-LacZ
mice precipitated both central and peripheral tolerance.
EC-independent peripheral CD8 T-cell tolerance
Peripheral CD8 T-cell tolerance can be induced via different cell
types, including circulating hematopoietic cells expressing
mhAg,39,40 BM-derived APC cross-presenting antigen derived from
parenchymal tissues,41,42 or particular subsets of ECs that also
possess the ability to cross-present circulating antigens.8,14 In order
to assess truly EC-mediated peripheral tolerance induction, we
established first a highly sensitive in vivo restimulation assay to
detect very low amounts of circulating Bg1 cells. To this end,
graded numbers of sorted CD8Thy1.1 cells from naive Bg1 mice
were transferred into Thy1.2 Tie2-LacZ and C57BL/6 mice. At
6 days following adoptive transfer, mice were infected with
MCMV-LacZ, and the expansion of Bg1 cells was assessed 6 days
later. As shown in Figure 3A, -gal–specific CD8 T cells
expanded in C57BL/6 but not in Tie2-LacZ mice, confirming that
Bg1 cells encounter their antigen in Tie2-LacZ mice outside of the
Figure 2. CD8 T cell tolerance in Tie2-LacZ mice. Tie2-LacZ mice were crossed
with TCR-trangenic Bg1 mice. Thymocytes from Tie2-LacZ (T2; top row), Bg1 (middle
row), and Bg1  Tie2-LacZ mice (Bg1  T2; bottom row) were stained for CD4 and
CD8 expression. The expression of the transgenic V7 chain and binding of the
H2-Kb--gal96-103 tetramer was determined by gating on CD8 T cells. Values in the
top right quadrants indicate mean frequencies of CD4/CD8-positive cells in thymo-
cytes or percentage of antigen-specific cells in single CD8 thymocytes, respectively
(T2, n 	 2; Bg1, n 	 3; Bg1  T2, n 	 7). Splenocytes were assessed for V7 and
CD8 expression. Percentage of -gal96-103–specific cells was determined by V7 and
H2-Kb--gal96-103 tetramer staining, gating on CD8 T cells (T2, n 	 3; Bg1, n 	 5;
Bg1  T2, n 	 9).
Figure 3. Loss of adoptively transferred Bg1 CD8 T cells in Tie2-LacZ mice is
not dependent on -gal expression by ECs. (A) Graded numbers of CD8 Bg1
cells expressing the congenic marker Thy1.1 were adoptively transferred into
Thy1.2 C57BL/6 or Tie2-LacZ recipient mice. At 6 days later, mice were challenged
with 2  106 pfu MCMV-LacZ, and the proliferation of Bg1 CD8 T cells was
determined on day 6 following immunization by staining for CD8, Thy1.1, and the
transgenic V7 chain. Representative data from one of 2 independent experiments
are shown. (B,C) Adoptive transfer of Bg1 CD8 T cells in BM chimeric mice. A total of
5  104 (B) or 105 (C) TCR transgenic Thy1.1 Bg1 cells were adoptively transferred
intravenously into the indicated Thy1.2 BM chimeric mice. At 9 days (B) or 30 days
(C) later, mice were challenged with 2  106 pfu MCMV-LacZ, and proliferation of
Bg1 CD8 T cells was determined on day 6 following MCMV-LacZ challenge in the
indicated organs. Values represent mean percentage ( SEM) of Thy1.1V7 cells
within the CD8 T-cell compartment.
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thymus, and that this interaction leads to their deletion. However,
reconstituting Tie2-LacZ mice with C57BL/6 BM (B63 T2)
revealed that CD8 T-cell tolerance in Tie2-LacZ mice was solely
dependent on -gal expression within the BM (Figure 3B,C). In
addition, -gal expression by ECs in B63 T2 chimeric mice did
not affect the pattern of responsiveness of adoptively transferred
Bg1 cells following MCMV-LacZ infection (Figure S5). Taken
together, these data indicate that expression of an mhAg by ECs
alone is not sufficient to directly tolerize CD8 T cells, nor is this
antigen available to BM-derived APCs in a way that would lead to
CD8 T-cell tolerance.
ECs fail to directly activate naive CD8 T cells in vivo
Deletional tolerization of CD8 T cells via activation-induced cell
death is usually associated with a transient period of T-cell
activation and proliferation.24,43 Furthermore, it is possible that ECs
in Tie2-LacZ mice might directly interact with CD8 T cells in a
way that leads to T-cell activation and/or proliferation. In order to
assess a potential spontaneous T-cell activation by ECs in a
GVHD-like model situation, 3  106 CFSE-labeled TCR-
transgenic CD8 T cells were adoptively transferred into Tie2-
LacZ mice, and T-cell activation was monitored as CD44 up-
regulation on proliferating Bg1 cells (Figure 4A). Furthermore,
monitoring of CD44 up-regulation, expression of annexin V, and
enumeration of the total numbers of Bg1 cells in spleens at later
time points revealed that Bg1 T cells did not progress toward
activation-induced cell death (Figure S6). Quantification of -gal–
dependent T-cell proliferation was achieved by adoptive transfer of
CSFE-labeled, Thy1.1 CD8 Bg1 cells into either C57BL/6 or
Tie2-LacZ mice (Figure 3B). This sensitive read-out system was
then used to assess whether antigen presentation by ECs alone is
sufficient to mediate CD8 T-cell activation or whether BM-
derived APCs, in particular DCs, contribute to the observed initial
CD8 T-cell triggering.
An array of BM chimeric mice was generated using different
combinations between C57BL/6 (B6) and Tie2-LacZ (T2) controls,
Tie2-LacZ mice on the C57BL/6bm1 background (T2bm1) exhibit-
ing a mutated H2-Kb molecule that precludes H2-Kb-restricted
presentation, and CD11c-DTR mice,27 which facilitate the specific
ablation of CD11c DCs in lymphoid organs. As expected, Bg1
cells were not activated in B63 B6 chimeras (Figure 5A),
Figure 4. Activation of Bg1 CD8 T cells in Tie2-LacZ mice. (A) A total of 1.5  107
CFSE-labeled splenocytes (corresponding to 3  106 CD8 TCR-transgenic T cells)
from Bg1 mice were adoptively transferred into C57BL/6 or Tie2-LacZ mice. Mice
were killed on day 4 following transfer and cells from blood, spleen, and lymph nodes
were analyzed by flow cytometry for CFSE dilution and CD44 up-regulation on CD8
lymphocytes. Representative FACS plots from one representative of 2 independent
experiments are shown. (B) Quantification of Bg1 T-cell proliferation. A total of
1.5  107 CFSE-labeled Bg1 Thy1.1 splenocytes were injected into C57BL/6 or
naive Tie2-LacZ mice. Mice were killed on day 4 following transfer and cells from
blood, spleen, and lymph nodes were analyzed by flow cytometry. Values represent
mean percentage ( SEM, n 	 7; pooled data from 2 independent experiments) of
proliferating CD8Thy1.1 cells (*P 
 .05; **P 
 .005; ***P 
 .001).
Figure 5. In vivo proliferation of Bg1 CD8 T cells in BM chimeric mice. A total of 1.5  107 CFSE-labeled splenocytes (corresponding to 3  106 CD8 TCR-transgenic
T cells) expressing the congenic marker Thy1.1 were adoptively transferred into the indicated Thy1.2 bone marrow chimeras. (A) C57BL/63C57BL/6 (B63 B6).
(B) Tie2-LacZ3 Tie2LacZ (T23 T2). (C) C57BL/63 Tie2-LacZ (B63 T2). (D) Tie2-LacZ  B6.C-H2bm13 Tie2-LacZ (T2  bm13 T2). (E) Tie2-LacZ  B6.C-H2bm13 Tie2-
LacZ  B6.C-H2bm1 (T2  bm1 3 T2  bm1). (F) C57BL/6 3 Tie2-LacZ  B6.C-H2bm1 (B6 3 T2  bm1). (G) CD11c DTR 3 Tie2-LacZ  B6.C-H2bm1
(CD11cDTR3 T2  bm1). CD11c-DTR BM recipients had been injected intraperitoneally with 4 ng/g body weight diphteria toxin (DT), which led to a 95% to 98% depletion of
CD11c cells for more than 48 hours. Mice were killed on day 4 following adoptive transfer and cells from blood and spleens were analyzed by flow cytometry. Values in the
histograms represent mean percentages ( SEM, n 	 5-7; pooled data from 3 independent experiments) of proliferating CD8Thy1.1 cells.
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whereas transgenic CD8 T cells proliferated in T23 T2 chimeric
mice (Figure 5B). Proliferation of Bg1 cells in B63 T2 chimeras
indicated that BM-derived nontransgenic APCs had activated the
transgenic T cells (Figure 5C). This interpretation is supported by
the fact that Bg1 proliferation was aborted in T2bm13 T2
chimeras where direct and cross-presentation via BM-derived
APCs is abolished, and only ECs can present the -gal epitope
(Figure 5D). Experiments with T2bm13 T2bm1 chimeras con-
firmed that Bg1 cells do not proliferate in the absence of the
appropriate H2 restriction element (Figure 5E). Bg1 activation
could be restored in B63 T2bm1 chimeras, confirming that
BM-derived APCs are crucial in this setting (Figure 5F). Finally,
reconstitution of T2bm1 mice with BM from CD11c-DTR mice
together with diphteria toxin–mediated ablation of DCs showed
that the proliferation of Bg1 cells depended strictly on the
cross-presentation of -gal Ag by DCs (Figure 5G). It is notewor-
thy that Bg1 activation in B63 T2bm1 chimeras (Figure 5F) was
somewhat reduced compared with the proliferative activity ob-
served in B63 T2 chimeras (Figure 5C), suggesting that ECs
might to some extent contribute to the observed effects. Neverthe-
less, as a whole, the presented results indicate that -gal–
presenting vascular ECs remain immunologically ignored by CD8
T cells, and that activation and proliferation of CD8 T cells
recognizing the mhAg in Tie2-LacZ mice is almost exclusively
dependent on cross-presentation of Ag by BM-derived DCs.
Immunologic ignorance of antigen-expressing ECs in
vascularized organ transplants
In order to assess whether these findings, obtained in a GVHD-like
setting, also reflect EC-CTL interaction within vascularized organ
grafts, a series of heart and liver transplantations were performed.
Heterotopically transplanted Tie2-LacZ hearts were well-accepted
in C57BL/6 recipients and spontaneous CD8 T cells responses
against both the -gal497-503 (Figure 6A) and the -gal96-103 epitope
(not shown) could not be detected. To analyze with higher
sensitivity, the effect of -gal expression on vascular ECs, we used
the adoptive transfer system of CSFE-labeled Bg1 cells. At 2 weeks
following either heterotopic heart transplantation (Figure 6Bi,iii) or
orthotopic liver transplantation (Figure 6Bii,iv), CFSE-labeled Bg1
CD8 T cells were adoptively transferred either into recipients that
had received C57BL/6 (Figure 6Bi,ii) or transgenic Tie2-LacZ
organs (Figure 6Biii,iv). This analysis revealed no significant
differences in Bg1 CD8 T-cell activation between recipients of
Tie2-LacZ and C57BL/6 control organs, indicating that ECs within
the transplanted organs had not primed naive CD8 T cells.
Discussion
In this study, we have used antigen-transgenic mice with uniform
mhAg expression in ECs in combination with CD8 T-cell TCR
transgenics to demonstrate that mhAg presentation by ECs does
neither precipitate T-cell activation nor tolerization. The lack of any
tolerizing effect of prolonged EC–CD8 T-cell interaction is
unexpected because nonactivated, mhAg-presenting ECs in Tie2-
LacZ provide “signal 1” (ie, antigen) in the absence of “signal 2”
(ie, costimulation). Thus, the EC-associated antigen in Tie2-LacZ
mice that is expressed in a widespread and easily accessible fashion
should lead to CD8 T-cell tolerance, in particular, in the absence
of “danger signals.”44 One could argue that ECs possess an
impaired capacity to present immunodominant peptides45 and
therefore fail to interact with CD8 T cells. However, ECs in
transplanted Tie2-LacZ organs can become target cells of CTLs
that had been primed with -gal peptide-pulsed DCs. Such a
treatment leads to vascular inflammatory disease with neointima
formation and vascular occlusion, suggesting that it is the DC-
mediated, prolonged presentation of mhAg within secondary
lymphoid organs that drives activation of EC-specific CTLs and
fosters thereby the development of chronic vascular rejection
(D Engeler et al, submitted manuscript). Furthermore, it is unlikely
that the antigen expression levels in ECs of Tie2-LacZ are too low
to allow for productive EC–CD8 T-cell interaction because sufficient
EC-associated antigen is present in Tie2-LacZ mice for indirect (cross-)
presentation by BM-derived DCs. It is therefore possible that studies
describing activation and subsequent tolerization of CD8 T cells,
for example by particular subsets of EC such as liver sinusoidal
ECs,8,14,15 may not have considered the contribution of professional
APCs such as DCs and other BM-derived APCs.
Figure 6. Lack of CD8 cell activation in naive recipients of Tie2-LacZ
vascularized organ grafts. (A) Spontaneous -gal–specific CD8 T-cell reactivity
measured by tetramer analysis. C57BL/6 recipients received either C57BL/6
(B63 B6) or Tie2-LacZ (T23 B6) hearts, and the presence of -gal497-504–specific
CD8 T cells in blood was assessed by flow cytometry on day 20 after transplanta-
tion. (B) Activation of CD8 Bg1 T cells after adoptive transfer of 1.5  107
CFSE-labeled Bg1 splenocytes in C57BL/6 recipients on day 10 after transplantation.
(i,iii) Heterotopic heart transplantation with donor organs from C57BL/6 (n 	 7, i) and
Tie2-LacZ (n 	 8, iii) mice. Orthotopic liver transplantation with donor organs from
C57BL/6 (n 	 5, i) and Tie2-LacZ (n 	 4, iii) mice. Mice were killed on day 4 following
adoptive transfer, and cells from blood were analyzed by flow cytometry. Values in the
histograms represent mean percentages ( SEM) of proliferating CD8Thy1.1
cells.
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Indeed, the complexity of the multicellular processes involved
in EC-mediated antigen presentation in vivo requires careful
consideration of possible confounding factors. Rothermel et al38
have suggested that immune recognition of ECs is context depen-
dent, with antigen expressed in hearts of Tie2-LacZ mice being
immunologically ignored, whereas ECs presenting -gal antigen in
skin are immunogenic and thus elicit T-cell responses capable of
rejecting skin grafts. The results of our study clearly confirm the
notion that direct presentation of mhAg by ECs is accompanied by
immunologic ignorance. However, in the context of mhAg presen-
tation in transplant vasculopathy and GVHD, DCs are probably the
most important cell population that cross-presents the antigen in an
immunogenic fashion.
Our study revealed further details that could confound the
analysis of T-cell activation/tolerization in Tie2-LacZ mice:
-gal–specific CD8 T cells were effectively tolerized in
nonirradiated Tie2-LacZ and in T23 T2 BM chimeric mice.
We conclude from these findings that cells within the BM, but
not professional APCs that descend from BM precursors, exert a
tolerizing stimulus in Tie2-LacZ mice. Hematopoietic stem cells
(HSCs) express the angiopoetin 1 receptor Tie2,46 and recent
studies have shown that the tie2 promoter that has been used in
Tie2-LacZ26 mice is active in HSCs during embryonic develop-
ment.47 Likewise, in BM of adult Tie2-LacZ mice, LacZ
transcripts were most abundant in HSCs (Figure S3). Thus, since
circulating lymphocytes presenting mhAg efficiently tolerize
naive CD8 T cells,24,40 it is reasonable to assume that naive
CD8 T cells traveling through the BM can receive tolerizing
stimuli within this compartment. Using Tie2-LacZ BM chime-
ras, it will be feasible to further characterize those cells within
the BM that are highly efficient in inducing tolerance to mhAg.
Taken together, this study identifies the initial priming of
mhAg-specific CD8 T cells via DCs as a critical step in the
generation of alloimmune responses. Therefore, it appears to be
crucial that therapeutic intervention should aim at preventing or at
least reducing the initial T-cell activation against mhAg. Indeed,
blockade of essential costimulatory pathways such as CD40-
CD15423,48 or CD28-CD80/8649 interaction during initial DC-
mediated CD8 T-cell stimulation bear a high potential for clinical
application. It may well be that a combination of costimulatory
blockade before and during priming of EC-specific CD8 cell
responses together with the induction of regulatory T cells49 will
help to protect ECs from injury following transplantation of
vascularized organs or during GVHD.
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